chrisvoncsefalvay/vaers-narrative-generation huggingface dataset:
Age: 77.0
Sex: M
Vaccine: COVID19
Symptoms: COVID-19, Vaccination failure
Clinical narrative: Cold symptoms; positive for COVID-19; Cold symptoms; positive for COVID-19; This is a spontaneous report received from contactable consumer. The reporter is the patient.  A 77-year-old male patient received BNT162b2, BNT162b2 omi ba.4-5 (BNT162B2, BNT162B2 OMI BA.4-5), on 15Sep2022 at 11:00 as dose 5 (booster), single (Lot number: GH9702) at the age of 77 years, in left arm for COVID-19 immunisation; BNT162b2 (BNT162B2), on 02Feb2021 at 15:45 as dose 1, single (Lot number: EL9264), in left arm, on 23Feb2021 at 13:45 as dose 2, single (Lot number: EN6203), in right arm, on 17Sep2021 at 15:00 as dose 3 (booster), single (Lot number: FD8448), in right arm and on 04Apr2022 at 11:00 as dose 4 (booster), single (Lot number: FJ9943), in left arm for COVID-19 immunisation. The patient's relevant medical history was not reported. The patient had no known allergies. Concomitant medication(s) included: LEVOXYL, start date: 12Sep2022, stop date: 08Oct2022; ACYCLOVIR [ACICLOVIR], start date: 12Sep2022, stop date: 08Oct2022; ASPIRIN [ACETYLSALICYLIC ACID], start date: 15Sep2022, stop date: 06Oct2022; SIMVASTATIN, start date: 12Sep2022, stop date: 08Oct2022; CENTRUM SILVER MEN 50+, start date: 12Sep2022, stop date: 08Oct2022; NORDIC NATURALS OMEGA 3, start date: 12Sep2022, stop date: 08Oct2022; NATURE'S BOUNTY B COMPLEX, start date: 12Sep2022, stop date: 08Oct2022; ELDERBERRY [SAMBUCUS NIGRA], start date: 12Sep2022, stop date: 08Oct2022; VITAMIN D [VITAMIN D NOS], start date: 12Sep2022, stop date: 08Oct2022; VITAMIN C WITH ROSE HIPS [ASCORBIC ACID], start date: 12Sep2022, stop date: 08Oct2022; GLUCOSAMINE & CHONDROITIN TRIPLE STRENGTH, start date: 12Sep2022, stop date: 08Oct2022; PSYLLIUM HUSK [PLANTAGO PSYLLIUM], start date: 12Sep2022, stop date: 08Oct2022; COQ10 [UBIDECARENONE], start date: 12Sep2022, stop date: 08Oct2022. The following information was reported: VACCINATION FAILURE (medically significant), COVID-19 (medically significant) all with onset 25Sep2022, outcome "recovered" (02Oct2022) and all described as "Cold symptoms; positive for COVID-19". The patient underwent the following laboratory tests and procedures: SARS-CoV-2 test: (26Sep2022) Positive; (02Oct2022) Negative; (03Oct2022) Negative; (04Oct2022) Negative; (05Oct2022) Negative. Therapeutic measures were taken as a result of vaccination failure, COVID-19. Per clinical course, the patient started having cold symptoms while on a trip on 25Sep2022. The patient and his wife flew home that afternoon. They got home around 1:00 AM on 26Sep2022. The patient was very congested. The next morning, the patient and his wife got rapid tests at a pharmacy. The patient was positive, but his wife was negative. The physician prescribed nirmatrelvir/ ritonavir (PAXLOVID) which she began that night 26Sep2022. The patient finished the regimen on Saturday morning (01Oct2022). Symptoms subsided on 28Sep2022. The patient was negative from 02Oct2022 to 05Oct2022.
Age: 76.0
Sex: F
Vaccine: COVID19
Symptoms: COVID-19, Chemotherapy, Death, Dyspnoea, Positive airway pressure therapy
Clinical narrative: pt had been receiving chemotherapy for adrenal CA at the Hospital; was living in a nursing home; tested positive for COVID; taken to another Hospital 12/1/22 where she also tested positive for COVID; experienced SOB, was on BiPAP, suffered septic shock, now unresponsive; pt passed away at Hospice
Age: 76.0
Sex: F
Vaccine: COVID19
Symptoms: SARS-CoV-2 test positive, Septic shock, Unresponsive to stimuli
Clinical narrative: pt had been receiving chemotherapy for adrenal CA at the Hospital; was living in a nursing home; tested positive for COVID; taken to another Hospital 12/1/22 where she also tested positive for COVID; experienced SOB, was on BiPAP, suffered septic shock, now unresponsive; pt passed away at Hospice
Age: 38.0
Sex: M
Vaccine: COVID19, COVID19, COVID19, COVID19
Symptoms: Anxiety, Chest pain, Fatigue, Inappropriate schedule of product administration, Myocarditis
Clinical narrative: Extreme anxiety; Feeling heart in chest; Heavy legs; three days later had burning tingling in skin; Felt short of breath; prev dose administration date=04Nov2021, prev dose number=1, Date of start of drug: 18Dec2021, dose number: 2; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 38-year-old male patient received BNT162b2 (BNT162B2), on 18Dec2021 at 20:00 as dose 2, single (Lot number: 331808a) at the age of 38 years, in left arm for covid-19 immunisation. The patient's relevant medical history included: "Gastritis" (unspecified if ongoing). There were no concomitant medications. Vaccination history included: BNT162b2 (DOSE 1, SINGLE; Batch/Lot No: 320308d; Anatomical location: Arm left; administration Time: 08:00 PM), administration date: 04Nov2021, for Covid-19 immunization. The following information was reported: ANXIETY (non-serious) with onset 18Dec2021 at 20:30, outcome "not recovered", described as "Extreme anxiety"; MALAISE (non-serious) with onset 18Dec2021 at 20:30, outcome "not recovered", described as "Feeling heart in chest"; DYSPNOEA (non-serious) with onset 18Dec2021 at 20:30, outcome "not recovered", described as "Felt short of breath"; LIMB DISCOMFORT (non-serious) with onset 18Dec2021 at 20:30, outcome "not recovered", described as "Heavy legs"; INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (non-serious) with onset 18Dec2021 at 20:30, outcome "unknown", described as "prev dose administration date=04Nov2021, prev dose number=1, Date of start of drug: 18Dec2021, dose number: 2"; SKIN BURNING SENSATION (non-serious) with onset 18Dec2021 at 20:30, outcome "not recovered", described as "three days later had burning tingling in skin". The events "extreme anxiety", "feeling heart in chest", "heavy legs", "three days later had burning tingling in skin", "felt short of breath" and "prev dose administration date=04nov2021, prev dose number=1, date of start of drug: 18dec2021, dose number: 2" required emergency room visit. Relevant laboratory tests and procedures are available in the appropriate section. Therapeutic measures were not taken as a result of anxiety, malaise, limb discomfort, skin burning sensation, dyspnoea.  Additional information: There were no known allergies.There were no other vaccine in fourweeks.   Follow-up attempts are completed. No further information is expected.; Sender's Comments: Linked Report(s) : US-PFIZER INC-202201214141 Same patient/drug, different AE, different dose of vaccine;
Age: 38.0
Sex: M
Vaccine: COVID19, COVID19, COVID19, COVID19
Symptoms: Panic attack, Respiratory tract congestion
Clinical narrative: Extreme anxiety; Feeling heart in chest; Heavy legs; three days later had burning tingling in skin; Felt short of breath; prev dose administration date=04Nov2021, prev dose number=1, Date of start of drug: 18Dec2021, dose number: 2; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 38-year-old male patient received BNT162b2 (BNT162B2), on 18Dec2021 at 20:00 as dose 2, single (Lot number: 331808a) at the age of 38 years, in left arm for covid-19 immunisation. The patient's relevant medical history included: "Gastritis" (unspecified if ongoing). There were no concomitant medications. Vaccination history included: BNT162b2 (DOSE 1, SINGLE; Batch/Lot No: 320308d; Anatomical location: Arm left; administration Time: 08:00 PM), administration date: 04Nov2021, for Covid-19 immunization. The following information was reported: ANXIETY (non-serious) with onset 18Dec2021 at 20:30, outcome "not recovered", described as "Extreme anxiety"; MALAISE (non-serious) with onset 18Dec2021 at 20:30, outcome "not recovered", described as "Feeling heart in chest"; DYSPNOEA (non-serious) with onset 18Dec2021 at 20:30, outcome "not recovered", described as "Felt short of breath"; LIMB DISCOMFORT (non-serious) with onset 18Dec2021 at 20:30, outcome "not recovered", described as "Heavy legs"; INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (non-serious) with onset 18Dec2021 at 20:30, outcome "unknown", described as "prev dose administration date=04Nov2021, prev dose number=1, Date of start of drug: 18Dec2021, dose number: 2"; SKIN BURNING SENSATION (non-serious) with onset 18Dec2021 at 20:30, outcome "not recovered", described as "three days later had burning tingling in skin". The events "extreme anxiety", "feeling heart in chest", "heavy legs", "three days later had burning tingling in skin", "felt short of breath" and "prev dose administration date=04nov2021, prev dose number=1, date of start of drug: 18dec2021, dose number: 2" required emergency room visit. Relevant laboratory tests and procedures are available in the appropriate section. Therapeutic measures were not taken as a result of anxiety, malaise, limb discomfort, skin burning sensation, dyspnoea.  Additional information: There were no known allergies.There were no other vaccine in fourweeks.   Follow-up attempts are completed. No further information is expected.; Sender's Comments: Linked Report(s) : US-PFIZER INC-202201214141 Same patient/drug, different AE, different dose of vaccine;
Age: 38.0
Sex: M
Vaccine: COVID19, COVID19, COVID19, COVID19
Symptoms: Anxiety, Electrocardiogram normal, Palpitations
Clinical narrative: Extreme anxiety; Feeling heart in chest; Heavy legs; three days later had burning tingling in skin; Felt short of breath; prev dose administration date=04Nov2021, prev dose number=1, Date of start of drug: 18Dec2021, dose number: 2; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 38-year-old male patient received BNT162b2 (BNT162B2), on 18Dec2021 at 20:00 as dose 2, single (Lot number: 331808a) at the age of 38 years, in left arm for covid-19 immunisation. The patient's relevant medical history included: "Gastritis" (unspecified if ongoing). There were no concomitant medications. Vaccination history included: BNT162b2 (DOSE 1, SINGLE; Batch/Lot No: 320308d; Anatomical location: Arm left; administration Time: 08:00 PM), administration date: 04Nov2021, for Covid-19 immunization. The following information was reported: ANXIETY (non-serious) with onset 18Dec2021 at 20:30, outcome "not recovered", described as "Extreme anxiety"; MALAISE (non-serious) with onset 18Dec2021 at 20:30, outcome "not recovered", described as "Feeling heart in chest"; DYSPNOEA (non-serious) with onset 18Dec2021 at 20:30, outcome "not recovered", described as "Felt short of breath"; LIMB DISCOMFORT (non-serious) with onset 18Dec2021 at 20:30, outcome "not recovered", described as "Heavy legs"; INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (non-serious) with onset 18Dec2021 at 20:30, outcome "unknown", described as "prev dose administration date=04Nov2021, prev dose number=1, Date of start of drug: 18Dec2021, dose number: 2"; SKIN BURNING SENSATION (non-serious) with onset 18Dec2021 at 20:30, outcome "not recovered", described as "three days later had burning tingling in skin". The events "extreme anxiety", "feeling heart in chest", "heavy legs", "three days later had burning tingling in skin", "felt short of breath" and "prev dose administration date=04nov2021, prev dose number=1, date of start of drug: 18dec2021, dose number: 2" required emergency room visit. Relevant laboratory tests and procedures are available in the appropriate section. Therapeutic measures were not taken as a result of anxiety, malaise, limb discomfort, skin burning sensation, dyspnoea.  Additional information: There were no known allergies.There were no other vaccine in fourweeks.   Follow-up attempts are completed. No further information is expected.; Sender's Comments: Linked Report(s) : US-PFIZER INC-202201214141 Same patient/drug, different AE, different dose of vaccine;
Age: 38.0
Sex: M
Vaccine: COVID19, COVID19, COVID19, COVID19
Symptoms: COVID-19, Drug ineffective, Nasopharyngeal swab
Clinical narrative: Extreme anxiety; Feeling heart in chest; Heavy legs; three days later had burning tingling in skin; Felt short of breath; prev dose administration date=04Nov2021, prev dose number=1, Date of start of drug: 18Dec2021, dose number: 2; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 38-year-old male patient received BNT162b2 (BNT162B2), on 18Dec2021 at 20:00 as dose 2, single (Lot number: 331808a) at the age of 38 years, in left arm for covid-19 immunisation. The patient's relevant medical history included: "Gastritis" (unspecified if ongoing). There were no concomitant medications. Vaccination history included: BNT162b2 (DOSE 1, SINGLE; Batch/Lot No: 320308d; Anatomical location: Arm left; administration Time: 08:00 PM), administration date: 04Nov2021, for Covid-19 immunization. The following information was reported: ANXIETY (non-serious) with onset 18Dec2021 at 20:30, outcome "not recovered", described as "Extreme anxiety"; MALAISE (non-serious) with onset 18Dec2021 at 20:30, outcome "not recovered", described as "Feeling heart in chest"; DYSPNOEA (non-serious) with onset 18Dec2021 at 20:30, outcome "not recovered", described as "Felt short of breath"; LIMB DISCOMFORT (non-serious) with onset 18Dec2021 at 20:30, outcome "not recovered", described as "Heavy legs"; INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (non-serious) with onset 18Dec2021 at 20:30, outcome "unknown", described as "prev dose administration date=04Nov2021, prev dose number=1, Date of start of drug: 18Dec2021, dose number: 2"; SKIN BURNING SENSATION (non-serious) with onset 18Dec2021 at 20:30, outcome "not recovered", described as "three days later had burning tingling in skin". The events "extreme anxiety", "feeling heart in chest", "heavy legs", "three days later had burning tingling in skin", "felt short of breath" and "prev dose administration date=04nov2021, prev dose number=1, date of start of drug: 18dec2021, dose number: 2" required emergency room visit. Relevant laboratory tests and procedures are available in the appropriate section. Therapeutic measures were not taken as a result of anxiety, malaise, limb discomfort, skin burning sensation, dyspnoea.  Additional information: There were no known allergies.There were no other vaccine in fourweeks.   Follow-up attempts are completed. No further information is expected.; Sender's Comments: Linked Report(s) : US-PFIZER INC-202201214141 Same patient/drug, different AE, different dose of vaccine;
Age: 38.0
Sex: M
Vaccine: COVID19, COVID19, COVID19, COVID19
Symptoms: Anxiety, Dyspnoea, Inappropriate schedule of product administration, Limb discomfort, Malaise
Clinical narrative: Extreme anxiety; Feeling heart in chest; Heavy legs; three days later had burning tingling in skin; Felt short of breath; prev dose administration date=04Nov2021, prev dose number=1, Date of start of drug: 18Dec2021, dose number: 2; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 38-year-old male patient received BNT162b2 (BNT162B2), on 18Dec2021 at 20:00 as dose 2, single (Lot number: 331808a) at the age of 38 years, in left arm for covid-19 immunisation. The patient's relevant medical history included: "Gastritis" (unspecified if ongoing). There were no concomitant medications. Vaccination history included: BNT162b2 (DOSE 1, SINGLE; Batch/Lot No: 320308d; Anatomical location: Arm left; administration Time: 08:00 PM), administration date: 04Nov2021, for Covid-19 immunization. The following information was reported: ANXIETY (non-serious) with onset 18Dec2021 at 20:30, outcome "not recovered", described as "Extreme anxiety"; MALAISE (non-serious) with onset 18Dec2021 at 20:30, outcome "not recovered", described as "Feeling heart in chest"; DYSPNOEA (non-serious) with onset 18Dec2021 at 20:30, outcome "not recovered", described as "Felt short of breath"; LIMB DISCOMFORT (non-serious) with onset 18Dec2021 at 20:30, outcome "not recovered", described as "Heavy legs"; INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (non-serious) with onset 18Dec2021 at 20:30, outcome "unknown", described as "prev dose administration date=04Nov2021, prev dose number=1, Date of start of drug: 18Dec2021, dose number: 2"; SKIN BURNING SENSATION (non-serious) with onset 18Dec2021 at 20:30, outcome "not recovered", described as "three days later had burning tingling in skin". The events "extreme anxiety", "feeling heart in chest", "heavy legs", "three days later had burning tingling in skin", "felt short of breath" and "prev dose administration date=04nov2021, prev dose number=1, date of start of drug: 18dec2021, dose number: 2" required emergency room visit. Relevant laboratory tests and procedures are available in the appropriate section. Therapeutic measures were not taken as a result of anxiety, malaise, limb discomfort, skin burning sensation, dyspnoea.  Additional information: There were no known allergies.There were no other vaccine in fourweeks.   Follow-up attempts are completed. No further information is expected.; Sender's Comments: Linked Report(s) : US-PFIZER INC-202201214141 Same patient/drug, different AE, different dose of vaccine;
Age: 38.0
Sex: M
Vaccine: COVID19, COVID19, COVID19, COVID19
Symptoms: Nasopharyngeal swab, Skin burning sensation
Clinical narrative: Extreme anxiety; Feeling heart in chest; Heavy legs; three days later had burning tingling in skin; Felt short of breath; prev dose administration date=04Nov2021, prev dose number=1, Date of start of drug: 18Dec2021, dose number: 2; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 38-year-old male patient received BNT162b2 (BNT162B2), on 18Dec2021 at 20:00 as dose 2, single (Lot number: 331808a) at the age of 38 years, in left arm for covid-19 immunisation. The patient's relevant medical history included: "Gastritis" (unspecified if ongoing). There were no concomitant medications. Vaccination history included: BNT162b2 (DOSE 1, SINGLE; Batch/Lot No: 320308d; Anatomical location: Arm left; administration Time: 08:00 PM), administration date: 04Nov2021, for Covid-19 immunization. The following information was reported: ANXIETY (non-serious) with onset 18Dec2021 at 20:30, outcome "not recovered", described as "Extreme anxiety"; MALAISE (non-serious) with onset 18Dec2021 at 20:30, outcome "not recovered", described as "Feeling heart in chest"; DYSPNOEA (non-serious) with onset 18Dec2021 at 20:30, outcome "not recovered", described as "Felt short of breath"; LIMB DISCOMFORT (non-serious) with onset 18Dec2021 at 20:30, outcome "not recovered", described as "Heavy legs"; INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (non-serious) with onset 18Dec2021 at 20:30, outcome "unknown", described as "prev dose administration date=04Nov2021, prev dose number=1, Date of start of drug: 18Dec2021, dose number: 2"; SKIN BURNING SENSATION (non-serious) with onset 18Dec2021 at 20:30, outcome "not recovered", described as "three days later had burning tingling in skin". The events "extreme anxiety", "feeling heart in chest", "heavy legs", "three days later had burning tingling in skin", "felt short of breath" and "prev dose administration date=04nov2021, prev dose number=1, date of start of drug: 18dec2021, dose number: 2" required emergency room visit. Relevant laboratory tests and procedures are available in the appropriate section. Therapeutic measures were not taken as a result of anxiety, malaise, limb discomfort, skin burning sensation, dyspnoea.  Additional information: There were no known allergies.There were no other vaccine in fourweeks.   Follow-up attempts are completed. No further information is expected.; Sender's Comments: Linked Report(s) : US-PFIZER INC-202201214141 Same patient/drug, different AE, different dose of vaccine;
Age: 25.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: COVID-19, SARS-CoV-2 test positive
Clinical narrative: SORE THROAT, COUGH, SNIFFLES
Age: 25.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Cough, Oropharyngeal pain, Rhinorrhoea
Clinical narrative: SORE THROAT, COUGH, SNIFFLES
Age: 53.0
Sex: F
Vaccine: COVID19, COVID19, COVID19
Symptoms: Back pain, Fatigue, Gait disturbance, Somnolence
Clinical narrative: one day after vaccination #2, the second vaccination of Pfizer product, my low back muscles began to cramp. I went to an urgent care facility on the 3rd day of it not getting any better. I was given an injection to relax muscles, a steriod injection, and sent home with non-narcotic muscle relaxers. I was able to return to work in a week.  two days after the booster shot (#3), my low back muscles tightened up again and was more severe. I had trouble walking by day 3. Went to the ER ; was given prescription for non-narcotic muscle relaxers and a prescription for an anti-inflammatory. It was a slow recovery, but I was able to go back to work in a week.
Age: 53.0
Sex: F
Vaccine: COVID19, COVID19, COVID19
Symptoms: Arthritis, Gait disturbance, Impaired work ability, Intervertebral disc degeneration, Muscle spasms
Clinical narrative: one day after vaccination #2, the second vaccination of Pfizer product, my low back muscles began to cramp. I went to an urgent care facility on the 3rd day of it not getting any better. I was given an injection to relax muscles, a steriod injection, and sent home with non-narcotic muscle relaxers. I was able to return to work in a week.  two days after the booster shot (#3), my low back muscles tightened up again and was more severe. I had trouble walking by day 3. Went to the ER ; was given prescription for non-narcotic muscle relaxers and a prescription for an anti-inflammatory. It was a slow recovery, but I was able to go back to work in a week.
Age: 53.0
Sex: F
Vaccine: COVID19, COVID19, COVID19
Symptoms: Muscle tightness, Spinal X-ray abnormal
Clinical narrative: one day after vaccination #2, the second vaccination of Pfizer product, my low back muscles began to cramp. I went to an urgent care facility on the 3rd day of it not getting any better. I was given an injection to relax muscles, a steriod injection, and sent home with non-narcotic muscle relaxers. I was able to return to work in a week.  two days after the booster shot (#3), my low back muscles tightened up again and was more severe. I had trouble walking by day 3. Went to the ER ; was given prescription for non-narcotic muscle relaxers and a prescription for an anti-inflammatory. It was a slow recovery, but I was able to go back to work in a week.
Age: 87.0
Sex: M
Vaccine: COVID19, COVID19, COVID19, COVID19, COVID19
Symptoms: COVID-19, Confusional state, Dyspnoea, SARS-CoV-2 test positive
Clinical narrative: Symptoms include shortness of breath and confusion in mental status.
Age: 87.0
Sex: M
Vaccine: COVID19, COVID19, COVID19, COVID19, COVID19
Symptoms: Confusional state, Dyspnoea, Mental status changes, SARS-CoV-2 RNA, SARS-CoV-2 test
Clinical narrative: Symptoms include shortness of breath and confusion in mental status.
Age: 75.0
Sex: F
Vaccine: COVID19, COVID19, COVID19
Symptoms: Chills, Influenza like illness, Pain in extremity, Rash
Clinical narrative: Flu like symptoms; Chills; This spontaneous case was reported by a patient and describes the occurrence of INFLUENZA LIKE ILLNESS (Flu like symptoms) and CHILLS (Chills) in a 75-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 008B21-2A and 026A21A) for COVID-19 vaccination.     The patient had not COVID positive test or diagnosis.  Concurrent medical conditions included Drug intolerance (Dilaudid) and Herbal allergy (herbal tea (rash)). Concomitant products included ROSUVASTATIN, IRBESARTAN and CALCIUM for an unknown indication.   On 05-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) .5 milliliter. On 02-Apr-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to .5 milliliter. On an unknown date, the patient experienced INFLUENZA LIKE ILLNESS (Flu like symptoms) and CHILLS (Chills). At the time of the report, INFLUENZA LIKE ILLNESS (Flu like symptoms) and CHILLS (Chills) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   Patient experienced chills and flu like symptoms with all the Moderna shots she has received so far.  She says that none of them concerned her that much as they were all expected reactions to the shots.  No treatment medications were reported.   This case was linked to MOD-2022-657079, MOD-2022-657016 (Patient Link).
Age: 75.0
Sex: F
Vaccine: COVID19, COVID19, COVID19
Symptoms: Chills, Influenza like illness
Clinical narrative: Flu like symptoms; Chills; This spontaneous case was reported by a patient and describes the occurrence of INFLUENZA LIKE ILLNESS (Flu like symptoms) and CHILLS (Chills) in a 75-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 008B21-2A and 026A21A) for COVID-19 vaccination.     The patient had not COVID positive test or diagnosis.  Concurrent medical conditions included Drug intolerance (Dilaudid) and Herbal allergy (herbal tea (rash)). Concomitant products included ROSUVASTATIN, IRBESARTAN and CALCIUM for an unknown indication.   On 05-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) .5 milliliter. On 02-Apr-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to .5 milliliter. On an unknown date, the patient experienced INFLUENZA LIKE ILLNESS (Flu like symptoms) and CHILLS (Chills). At the time of the report, INFLUENZA LIKE ILLNESS (Flu like symptoms) and CHILLS (Chills) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   Patient experienced chills and flu like symptoms with all the Moderna shots she has received so far.  She says that none of them concerned her that much as they were all expected reactions to the shots.  No treatment medications were reported.   This case was linked to MOD-2022-657079, MOD-2022-657016 (Patient Link).
Age: 75.0
Sex: F
Vaccine: COVID19, COVID19, COVID19
Symptoms: Chills, Claustrophobia, Dyspnoea, Feeling abnormal, Influenza like illness
Clinical narrative: Flu like symptoms; Chills; This spontaneous case was reported by a patient and describes the occurrence of INFLUENZA LIKE ILLNESS (Flu like symptoms) and CHILLS (Chills) in a 75-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 008B21-2A and 026A21A) for COVID-19 vaccination.     The patient had not COVID positive test or diagnosis.  Concurrent medical conditions included Drug intolerance (Dilaudid) and Herbal allergy (herbal tea (rash)). Concomitant products included ROSUVASTATIN, IRBESARTAN and CALCIUM for an unknown indication.   On 05-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) .5 milliliter. On 02-Apr-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to .5 milliliter. On an unknown date, the patient experienced INFLUENZA LIKE ILLNESS (Flu like symptoms) and CHILLS (Chills). At the time of the report, INFLUENZA LIKE ILLNESS (Flu like symptoms) and CHILLS (Chills) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   Patient experienced chills and flu like symptoms with all the Moderna shots she has received so far.  She says that none of them concerned her that much as they were all expected reactions to the shots.  No treatment medications were reported.   This case was linked to MOD-2022-657079, MOD-2022-657016 (Patient Link).
Age: 75.0
Sex: F
Vaccine: COVID19, COVID19, COVID19
Symptoms: Insomnia, Malaise, Nasopharyngitis, Uterine hypotonus, Uterine spasm
Clinical narrative: Flu like symptoms; Chills; This spontaneous case was reported by a patient and describes the occurrence of INFLUENZA LIKE ILLNESS (Flu like symptoms) and CHILLS (Chills) in a 75-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 008B21-2A and 026A21A) for COVID-19 vaccination.     The patient had not COVID positive test or diagnosis.  Concurrent medical conditions included Drug intolerance (Dilaudid) and Herbal allergy (herbal tea (rash)). Concomitant products included ROSUVASTATIN, IRBESARTAN and CALCIUM for an unknown indication.   On 05-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) .5 milliliter. On 02-Apr-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to .5 milliliter. On an unknown date, the patient experienced INFLUENZA LIKE ILLNESS (Flu like symptoms) and CHILLS (Chills). At the time of the report, INFLUENZA LIKE ILLNESS (Flu like symptoms) and CHILLS (Chills) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   Patient experienced chills and flu like symptoms with all the Moderna shots she has received so far.  She says that none of them concerned her that much as they were all expected reactions to the shots.  No treatment medications were reported.   This case was linked to MOD-2022-657079, MOD-2022-657016 (Patient Link).
Age: 75.0
Sex: F
Vaccine: COVID19, COVID19, COVID19
Symptoms: Vomiting
Clinical narrative: Flu like symptoms; Chills; This spontaneous case was reported by a patient and describes the occurrence of INFLUENZA LIKE ILLNESS (Flu like symptoms) and CHILLS (Chills) in a 75-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 008B21-2A and 026A21A) for COVID-19 vaccination.     The patient had not COVID positive test or diagnosis.  Concurrent medical conditions included Drug intolerance (Dilaudid) and Herbal allergy (herbal tea (rash)). Concomitant products included ROSUVASTATIN, IRBESARTAN and CALCIUM for an unknown indication.   On 05-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) .5 milliliter. On 02-Apr-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to .5 milliliter. On an unknown date, the patient experienced INFLUENZA LIKE ILLNESS (Flu like symptoms) and CHILLS (Chills). At the time of the report, INFLUENZA LIKE ILLNESS (Flu like symptoms) and CHILLS (Chills) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   Patient experienced chills and flu like symptoms with all the Moderna shots she has received so far.  She says that none of them concerned her that much as they were all expected reactions to the shots.  No treatment medications were reported.   This case was linked to MOD-2022-657079, MOD-2022-657016 (Patient Link).
Age: 74.0
Sex: F
Vaccine: COVID19, COVID19, COVID19
Symptoms: Headache, Pain, Pyrexia
Clinical narrative: Feeling sick; Aches After booster/Pains After booster; Fever; Chills; Nausea; Patient was in bed for 2 days; This spontaneous case was reported by a patient and describes the occurrence of MALAISE (Feeling sick), PAIN (Aches After booster/Pains After booster), BEDRIDDEN (Patient was in bed for 2 days), PYREXIA (Fever) and CHILLS (Chills) in a 74-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 001B21A and 031M20A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     Patient not had COVID positive test or diagnosis. No other vaccines given within 1 month prior to Moderna COVID-19 vaccine.  Previously administered products included for Product used for unknown indication: SHINGRIX, SHINGRIX, Flu vaccine (had to take the low dose flu vaccine), Flu vaccine (had to take the low dose flu vaccine), Pneumonia vaccine and Pneumonia vaccine. Past adverse reactions to the above products included Fever with Flu vaccine, Pneumonia vaccine and SHINGRIX; and Vaccination adverse reaction with Flu vaccine, Pneumonia vaccine and SHINGRIX. Concurrent medical conditions included Blood pressure high, Acid reflux (oesophageal) and Drug allergy (Sulfa). Concomitant products included OMEPRAZOLE (PRILOSEC [OMEPRAZOLE]) for Acid reflux (oesophageal), SPIRONOLACTONE, LOSARTAN and HYDROCHLOROTHIAZIDE for Blood pressure high, VITAMIN D [VITAMIN D NOS] for an unknown indication.   On 13-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) .5 milliliter. On 13-Mar-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to .5 milliliter. On 28-Oct-2021, received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to .5 milliliter. On an unknown date, the patient experienced MALAISE (Feeling sick), PAIN (Aches After booster/Pains After booster), BEDRIDDEN (Patient was in bed for 2 days), PYREXIA (Fever), CHILLS (Chills) and NAUSEA (Nausea). The patient was treated with PARACETAMOL (TYLENOL) at an unspecified dose and frequency. At the time of the report, MALAISE (Feeling sick), PAIN (Aches After booster/Pains After booster), PYREXIA (Fever), CHILLS (Chills) and NAUSEA (Nausea) outcome was unknown and BEDRIDDEN (Patient was in bed for 2 days) had resolved.            Patient had similar events like fever and other reactions with Flu vaccine, shingles vaccine pneumonia vaccine and had to take the low dose flu vaccine.   This case was linked to US-MODERNATX, INC.-MOD-2022-657178 (E2B Linked Report). This case was linked to MOD-2022-656992, MOD-2022-656993 (Patient Link).; Sender's Comments:  US-MODERNATX, INC.-MOD-2022-657178:friends case
Age: 74.0
Sex: F
Vaccine: COVID19, COVID19, COVID19
Symptoms: Bedridden, Chills, Malaise, Nausea, Pain
Clinical narrative: Feeling sick; Aches After booster/Pains After booster; Fever; Chills; Nausea; Patient was in bed for 2 days; This spontaneous case was reported by a patient and describes the occurrence of MALAISE (Feeling sick), PAIN (Aches After booster/Pains After booster), BEDRIDDEN (Patient was in bed for 2 days), PYREXIA (Fever) and CHILLS (Chills) in a 74-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 001B21A and 031M20A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     Patient not had COVID positive test or diagnosis. No other vaccines given within 1 month prior to Moderna COVID-19 vaccine.  Previously administered products included for Product used for unknown indication: SHINGRIX, SHINGRIX, Flu vaccine (had to take the low dose flu vaccine), Flu vaccine (had to take the low dose flu vaccine), Pneumonia vaccine and Pneumonia vaccine. Past adverse reactions to the above products included Fever with Flu vaccine, Pneumonia vaccine and SHINGRIX; and Vaccination adverse reaction with Flu vaccine, Pneumonia vaccine and SHINGRIX. Concurrent medical conditions included Blood pressure high, Acid reflux (oesophageal) and Drug allergy (Sulfa). Concomitant products included OMEPRAZOLE (PRILOSEC [OMEPRAZOLE]) for Acid reflux (oesophageal), SPIRONOLACTONE, LOSARTAN and HYDROCHLOROTHIAZIDE for Blood pressure high, VITAMIN D [VITAMIN D NOS] for an unknown indication.   On 13-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) .5 milliliter. On 13-Mar-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to .5 milliliter. On 28-Oct-2021, received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to .5 milliliter. On an unknown date, the patient experienced MALAISE (Feeling sick), PAIN (Aches After booster/Pains After booster), BEDRIDDEN (Patient was in bed for 2 days), PYREXIA (Fever), CHILLS (Chills) and NAUSEA (Nausea). The patient was treated with PARACETAMOL (TYLENOL) at an unspecified dose and frequency. At the time of the report, MALAISE (Feeling sick), PAIN (Aches After booster/Pains After booster), PYREXIA (Fever), CHILLS (Chills) and NAUSEA (Nausea) outcome was unknown and BEDRIDDEN (Patient was in bed for 2 days) had resolved.            Patient had similar events like fever and other reactions with Flu vaccine, shingles vaccine pneumonia vaccine and had to take the low dose flu vaccine.   This case was linked to US-MODERNATX, INC.-MOD-2022-657178 (E2B Linked Report). This case was linked to MOD-2022-656992, MOD-2022-656993 (Patient Link).; Sender's Comments:  US-MODERNATX, INC.-MOD-2022-657178:friends case
Age: 74.0
Sex: F
Vaccine: COVID19, COVID19, COVID19
Symptoms: Pyrexia
Clinical narrative: Feeling sick; Aches After booster/Pains After booster; Fever; Chills; Nausea; Patient was in bed for 2 days; This spontaneous case was reported by a patient and describes the occurrence of MALAISE (Feeling sick), PAIN (Aches After booster/Pains After booster), BEDRIDDEN (Patient was in bed for 2 days), PYREXIA (Fever) and CHILLS (Chills) in a 74-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 001B21A and 031M20A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     Patient not had COVID positive test or diagnosis. No other vaccines given within 1 month prior to Moderna COVID-19 vaccine.  Previously administered products included for Product used for unknown indication: SHINGRIX, SHINGRIX, Flu vaccine (had to take the low dose flu vaccine), Flu vaccine (had to take the low dose flu vaccine), Pneumonia vaccine and Pneumonia vaccine. Past adverse reactions to the above products included Fever with Flu vaccine, Pneumonia vaccine and SHINGRIX; and Vaccination adverse reaction with Flu vaccine, Pneumonia vaccine and SHINGRIX. Concurrent medical conditions included Blood pressure high, Acid reflux (oesophageal) and Drug allergy (Sulfa). Concomitant products included OMEPRAZOLE (PRILOSEC [OMEPRAZOLE]) for Acid reflux (oesophageal), SPIRONOLACTONE, LOSARTAN and HYDROCHLOROTHIAZIDE for Blood pressure high, VITAMIN D [VITAMIN D NOS] for an unknown indication.   On 13-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) .5 milliliter. On 13-Mar-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to .5 milliliter. On 28-Oct-2021, received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to .5 milliliter. On an unknown date, the patient experienced MALAISE (Feeling sick), PAIN (Aches After booster/Pains After booster), BEDRIDDEN (Patient was in bed for 2 days), PYREXIA (Fever), CHILLS (Chills) and NAUSEA (Nausea). The patient was treated with PARACETAMOL (TYLENOL) at an unspecified dose and frequency. At the time of the report, MALAISE (Feeling sick), PAIN (Aches After booster/Pains After booster), PYREXIA (Fever), CHILLS (Chills) and NAUSEA (Nausea) outcome was unknown and BEDRIDDEN (Patient was in bed for 2 days) had resolved.            Patient had similar events like fever and other reactions with Flu vaccine, shingles vaccine pneumonia vaccine and had to take the low dose flu vaccine.   This case was linked to US-MODERNATX, INC.-MOD-2022-657178 (E2B Linked Report). This case was linked to MOD-2022-656992, MOD-2022-656993 (Patient Link).; Sender's Comments:  US-MODERNATX, INC.-MOD-2022-657178:friends case
Age: 74.0
Sex: F
Vaccine: COVID19, COVID19, COVID19
Symptoms: Cardiac stress test, Electrocardiogram, Heart rate, Palpitations, Ultrasound scan
Clinical narrative: Feeling sick; Aches After booster/Pains After booster; Fever; Chills; Nausea; Patient was in bed for 2 days; This spontaneous case was reported by a patient and describes the occurrence of MALAISE (Feeling sick), PAIN (Aches After booster/Pains After booster), BEDRIDDEN (Patient was in bed for 2 days), PYREXIA (Fever) and CHILLS (Chills) in a 74-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 001B21A and 031M20A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     Patient not had COVID positive test or diagnosis. No other vaccines given within 1 month prior to Moderna COVID-19 vaccine.  Previously administered products included for Product used for unknown indication: SHINGRIX, SHINGRIX, Flu vaccine (had to take the low dose flu vaccine), Flu vaccine (had to take the low dose flu vaccine), Pneumonia vaccine and Pneumonia vaccine. Past adverse reactions to the above products included Fever with Flu vaccine, Pneumonia vaccine and SHINGRIX; and Vaccination adverse reaction with Flu vaccine, Pneumonia vaccine and SHINGRIX. Concurrent medical conditions included Blood pressure high, Acid reflux (oesophageal) and Drug allergy (Sulfa). Concomitant products included OMEPRAZOLE (PRILOSEC [OMEPRAZOLE]) for Acid reflux (oesophageal), SPIRONOLACTONE, LOSARTAN and HYDROCHLOROTHIAZIDE for Blood pressure high, VITAMIN D [VITAMIN D NOS] for an unknown indication.   On 13-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) .5 milliliter. On 13-Mar-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to .5 milliliter. On 28-Oct-2021, received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to .5 milliliter. On an unknown date, the patient experienced MALAISE (Feeling sick), PAIN (Aches After booster/Pains After booster), BEDRIDDEN (Patient was in bed for 2 days), PYREXIA (Fever), CHILLS (Chills) and NAUSEA (Nausea). The patient was treated with PARACETAMOL (TYLENOL) at an unspecified dose and frequency. At the time of the report, MALAISE (Feeling sick), PAIN (Aches After booster/Pains After booster), PYREXIA (Fever), CHILLS (Chills) and NAUSEA (Nausea) outcome was unknown and BEDRIDDEN (Patient was in bed for 2 days) had resolved.            Patient had similar events like fever and other reactions with Flu vaccine, shingles vaccine pneumonia vaccine and had to take the low dose flu vaccine.   This case was linked to US-MODERNATX, INC.-MOD-2022-657178 (E2B Linked Report). This case was linked to MOD-2022-656992, MOD-2022-656993 (Patient Link).; Sender's Comments:  US-MODERNATX, INC.-MOD-2022-657178:friends case
Age: 74.0
Sex: F
Vaccine: COVID19, COVID19, COVID19
Symptoms: Headache, Pain, Pyrexia
Clinical narrative: 3 weeks after 1st dose my heart started beating out control and got up 160 or more beats per minutes.; This spontaneous case was reported by a patient and describes the occurrence of PALPITATIONS (3 weeks after 1st dose my heart started beating out control and got up 160 or more beats per minutes.) in a 74-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 031M20A) for COVID-19 vaccination.     The patient did not had COVID positive test or diagnosis ever.  Previously administered products included for Product used for unknown indication: FLU [INFLUENZA VACCINE] (Had other reactions with Flu vaccine and had to take the low dose flu vaccine.), pneumonia vaccine (Had other reactions with pneumonia vaccine.) and shingles vaccine (Had other reactions with shingles vaccine.). Past adverse reactions to the above products included Fever with FLU [INFLUENZA VACCINE], pneumonia vaccine and shingles vaccine. Concurrent medical conditions included Sulfonamide allergy, Acid reflux (esophageal) and Blood pressure high. Concomitant products included OMEPRAZOLE (PRILOSEC [OMEPRAZOLE]) for Acid reflux (esophageal), SPIRONOLACTONE, LOSARTAN and HYDROCHLOROTHIAZIDE for Blood pressure high, VITAMIN D NOS for an unknown indication.    On 13-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) .5 milliliter. In March 2021, the patient experienced PALPITATIONS (3 weeks after 1st dose my heart started beating out control and got up 160 or more beats per minutes.). At the time of the report, PALPITATIONS (3 weeks after 1st dose my heart started beating out control and got up 160 or more beats per minutes.) outcome was unknown.           mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosing remained unchanged.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   It was reported that 3 weeks after the 1st dose patient  heart started beating out control and got up 160 or more beats per minutes. Cardiologist believed that she might have experienced some cardiac injury at some point in her life.  No other vaccines were given within 1 month prior to Moderna COVID-19 vaccine.  Treatment medication information was reported.
Age: 74.0
Sex: F
Vaccine: COVID19, COVID19, COVID19
Symptoms: Bedridden, Chills, Malaise, Nausea, Pain
Clinical narrative: 3 weeks after 1st dose my heart started beating out control and got up 160 or more beats per minutes.; This spontaneous case was reported by a patient and describes the occurrence of PALPITATIONS (3 weeks after 1st dose my heart started beating out control and got up 160 or more beats per minutes.) in a 74-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 031M20A) for COVID-19 vaccination.     The patient did not had COVID positive test or diagnosis ever.  Previously administered products included for Product used for unknown indication: FLU [INFLUENZA VACCINE] (Had other reactions with Flu vaccine and had to take the low dose flu vaccine.), pneumonia vaccine (Had other reactions with pneumonia vaccine.) and shingles vaccine (Had other reactions with shingles vaccine.). Past adverse reactions to the above products included Fever with FLU [INFLUENZA VACCINE], pneumonia vaccine and shingles vaccine. Concurrent medical conditions included Sulfonamide allergy, Acid reflux (esophageal) and Blood pressure high. Concomitant products included OMEPRAZOLE (PRILOSEC [OMEPRAZOLE]) for Acid reflux (esophageal), SPIRONOLACTONE, LOSARTAN and HYDROCHLOROTHIAZIDE for Blood pressure high, VITAMIN D NOS for an unknown indication.    On 13-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) .5 milliliter. In March 2021, the patient experienced PALPITATIONS (3 weeks after 1st dose my heart started beating out control and got up 160 or more beats per minutes.). At the time of the report, PALPITATIONS (3 weeks after 1st dose my heart started beating out control and got up 160 or more beats per minutes.) outcome was unknown.           mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosing remained unchanged.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   It was reported that 3 weeks after the 1st dose patient  heart started beating out control and got up 160 or more beats per minutes. Cardiologist believed that she might have experienced some cardiac injury at some point in her life.  No other vaccines were given within 1 month prior to Moderna COVID-19 vaccine.  Treatment medication information was reported.